Market Overview

UPDATE: Bank of America Initiates Akorn at Buy on Product, Revenue Mix

Share:
Related AKRX
Drug Price Hike Concerns Spill Over Into Other Pharma Stocks
Benzinga's Top Downgrades
Box Is Worth Speculating On - Cramer's Lightning Round (8/23/16) (Seeking Alpha)

Bank of America initiated coverage on Akorn (NASDAQ: AKRX) with a Buy rating and a $18 price objective.

Bank of America commented, "We like AKRX's mix of niche pharma products in generic injectables and ophthalmology. We also like AKRX's diverse revenue base (generic/brand, Rx/OTC), low product concentration risk (top product contributes ~13% of revenues, vs. ~36% for HITK, IPXL), and targeted ex-US operations (sales and manufacturing), which set AKRX apart vs. its small generic peers. As such, we believe the recent pullback in the shares has created an attractive entry point for investors. While our thesis is based on AKRX as an independent entity, we see the company as an attractive asset in a consolidating generic pharma environment."

Akorn closed at $12.04 on Tuesday.

Latest Ratings for AKRX

DateFirmActionFromTo
Aug 2016Deutsche BankDowngradesBuyHold
Aug 2016Raymond JamesDowngradesOutperformMarket Perform
Mar 2016Leerink SwannMaintainsMarket Perform

View More Analyst Ratings for AKRX
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color Initiation Pre-Market Outlook Analyst Ratings

 

Related Articles (AKRX)

View Comments and Join the Discussion!